Non-Cryogenic Psilocybin Manufacturing via Grignard Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved, scalable, and reproducible methods for manufacturing chemically pure psilocybin suitable for medical use, as existing methods require cryogenic conditions that are not feasible on a commercial scale.
Innovation Solution
A method involving the use of a lithium chloride complex Grignard reagent to react psilocin with tetrabenzylpyrophosphate, followed by hydrogenation and crystallization, allowing the production of psilocybin at non-cryogenic temperatures and higher yields, with reduced impurities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If existing synthesis methods are used, then psilocybin can be manufactured, but cryogenic conditions are required which are not feasible on commercial scale
Solution Approach 1:
The patent changes the temperature parameter from cryogenic conditions to non-cryogenic conditions (0°C to 25°C) by modifying the synthesis method to use a Grignard reagent followed by hydrogenation, making the process commercially viable while maintaining product yield and purity
2Productivity
If existing synthesis methods are used, then psilocybin can be manufactured, but the process is not scalable to commercial production
Solution Approach 1:
The patent modifies reaction parameters including temperature (raising from cryogenic to 0-25°C), pressure (using atmospheric pressure hydrogenation), and reagent selection (Grignard reagent with lithium chloride complex) to enable scalable commercial production while maintaining efficiency
Solution Approach 2:
The patent replaces complex cryogenic mechanical systems with simpler atmospheric pressure hydrogenation using palladium catalyst, eliminating the need for specialized cryogenic equipment and enabling standard industrial manufacturing
3Manufacturing precision
If existing synthesis methods are used, then psilocybin can be manufactured, but chemical purity is insufficient for medical use
Solution Approach 1:
The patent extracts and removes impurity-forming steps from the synthesis pathway by using a streamlined two-step process (Grignard reaction followed by hydrogenation) that inherently produces fewer byproducts, achieving ≥99% chemical purity suitable for medical use
Solution Approach 2:
The patent uses readily available reagents (Grignard reagent, tetrabenzylpyrophosphate, palladium catalyst) that are easy to handle and dispose of, simplifying the purification process and reducing the need for complex purification equipment while achieving high product purity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves high chemical purity (≥99%) and yield (≥50%) of psilocybin, suitable for medical use, without the need for cryogenic conditions, making it scalable and commercially viable.
Implementation Method 1
mixing psilocin and tetrabenzylpyrophosphate (TBPP) in the presence of a Grignard reagent to form a reaction mixture
Implementation Method 2
subjecting the reaction mixture to hydrogen in the presence of a catalyst to form psilocybin
Implementation Method 3
subjecting the reaction mixture to hydrogen in the presence of a catalyst to form psilocybin
Implementation Method 4
crystallizing psilocybin from water, thereby forming a crystalline form of psilocybin
Data Source
AI summary
The present disclosure provides methods of manufacturing psilocybin and crystalline psilocybin via a reaction of psilocin and tetrabenzylpyrophosphate in the presence of lithium chloride complex Grignard reagent, which is followed by hydrogenation. Methods of producing psilocin from 4-hydroxyindole or 4-acetoxyindole are also provided.